NVCN - Neovasc Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9600
+0.0200 (+0.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.9400
Open2.9200
Bid2.8000 x 1100
Ask3.0000 x 2900
Day's Range2.9061 - 3.0200
52 Week Range2.3400 - 11.0000
Volume29,090
Avg. Volume56,569
Market Cap22.584M
Beta (3Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)-2.1610
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
  • Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019
    Newsfile

    Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and ...

  • GlobeNewswire

    Neovasc Named Finalist in Questex’s Fierce Innovation Awards LifeSciences Edition 2019

    Neovasc was recognized as a finalist in the category of Medical Device Innovation. Neovasc was selected as a finalist for its innovative Neovasc Reducer™ (the “Reducer”), a medical device developed for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.

  • GlobeNewswire

    Neovasc Reducer™ Featured In FOCUS Magazine

    Professor Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, explained to FOCUS readers in the supplement called “Medizinischer Fortschritt” how Reducer therapy helps patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of the Reducer therapy and highlighted that 75% of patients treated with Reducer feel better and experience less chest pain.

  • Neovasc Reducer(TM) Featured In FOCUS Magazine
    Newsfile

    Neovasc Reducer(TM) Featured In FOCUS Magazine

    Vancouver, British Columbia and Berlin, Germany--(Newsfile Corp. - November 26, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a supplement in the FOCUS Magazine, one of the three most widely circulated ...

  • Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola
    Newsfile

    Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

    Educational events featuring the Reducer hosted in Germany and Italy Vancouver, British Columbia, Coburg, Germany, and Cotignola, Italy--(Newsfile Corp. - November 22, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured during a program hosted ...

  • GlobeNewswire

    Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

    - Educational events featuring the Reducer hosted in Germany and Italy - VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, Nov. 22, 2019 -- via NEWMEDIAWIRE -- Neovasc,.

  • Do Institutions Own Shares In Neovasc Inc. (TSE:NVCN)?
    Simply Wall St.

    Do Institutions Own Shares In Neovasc Inc. (TSE:NVCN)?

    The big shareholder groups in Neovasc Inc. (TSE:NVCN) have power over the company. Institutions will often hold stock...

  • Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019
    Newsfile

    Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 19, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal ("TF/TS") Tiara™ ("Tiara") System was featured today in a tutorial session at the PCR London Valves 2019 meeting, which is taking place November ...

  • GlobeNewswire

    Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

    Anson Cheung, MD, Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia, and Principal Investigator for the Tiara Early Feasibility Study at St. Paul’s Hospital, Vancouver, BC, provided an update on the Tiara program as part of “Rapid fire - Latest updates from the world of TMVR,” a session focusing on early clinical outcomes of patients undergoing transcatheter mitral valve replacement and potential future device solutions. Outcome data was presented on 71 of the 80 high surgical risk patients who have been treated with TA Tiara in either the TIARA-I Early Feasibility Clinical Study, Compassionate Use cases, or the TIARA-II CE Mark Clinical Study.

  • GlobeNewswire

    Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

    VANCOUVER and MAINZ, Germany, Nov. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a new milestone has been reached in Germany with the 200th patient implant of the Neovasc Reducer™ (the "Reducer").

  • Neovasc Reducer(TM) Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany
    Newsfile

    Neovasc Reducer(TM) Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

    Vancouver, British Columbia and Mainz, Germany--(Newsfile Corp. - November 12, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a new milestone has been reached in Germany with the 200th patient implant of the Neovasc Reducer™ (the "Reducer")."Many refractory angina patients ...

  • Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates

    Neovasc (NVCN) delivered earnings and revenue surprises of 23.77% and -41.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Neovasc Announces Third Quarter 2019 Financial Results

    Vancouver, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2019. “The third quarter of 2019 was another one of significant progress for the Company as we build the clinical data around Tiara and expand our Reducer commercial presence,” said Fred Colen, President and Chief Executive Officer of Neovasc.

  • Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer
    Newsfile

    Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer

    Vancouver, British Columbia--(Newsfile Corp. - November 7, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of Bill Little as the Company's Chief Operating Officer, reporting directly to the CEO. Mr. Little is an accomplished global marketing executive with more ...

  • GlobeNewswire

    Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum

    VANCOUVER, BC, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in two institutional investor conferences in November. On Wednesday, November 20, Mr. Colen will be presenting at the 2019 Stifel Healthcare Conference in New York City at 4:10 p.m. EST.

  • Newsfile

    Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

    Vancouver, British Columbia--(Newsfile Corp. - November 5, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the company will be providing an update on its Transfemoral Trans-septal ("TF/TS") Tiara System at the PCR London Valves 2019 meeting, which takes place November ...

  • Zacks

    What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

    DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

  • What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
    Zacks

    What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?

    Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

  • AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
    Zacks

    AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

    AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

  • DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
    Zacks

    DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

    DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

  • GlobeNewswire

    Neovasc to Submit Full PMA Application for Neovasc Reducer™ in 2019

    VANCOUVER, Nov. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it intends to submit a full Premarket Approval application (“PMA”) to the U.S. Food and Drug Administration (“FDA”) for its Neovasc Reducer™ (“Reducer”) medical device for the treatment of refractory angina before the end of 2019. Neovasc has been meeting with the FDA to discuss potential options to bring Reducer to the U.S. market. Following the last Sprint discussion held with the FDA on October 9, 2019 and weighing all available options a final decision was made by the Company to pursue a full PMA application for this Breakthrough medical device.